- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03769051
Study on The Oral Immune Tolerance of CMPA Infants Using Amino Acid Formula
September 1, 2019 updated by: Peking University Third Hospital
The main purpose of this study was to observe the effect of amino acid formula on infants with cow's milk protein allergy; to evaluate the role of food avoidance and Open Food Challenge test in the diagnosis of infants with cow's milk protein allergy; to observe the allergic process in infants with cow's milk protein allergy and to explore the criteria for diagnosis and treatment.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a multi-center, prospective cohort study.
This study plans to recruit 200 subjects.
The suitable subject will be enrolled and there are seven visits through the 6-month study.
Efficacy parameters are the positive incidence of open food challenge test, growth and development index (Weight, Height, Head circumference;), and the improvement of CMPA symptoms (such as SCORAD, gastrointestinal tract, respiratory, comfort scores).
Study Type
Observational
Enrollment (Actual)
200
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 6 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Cow's milk protein allergy infants in 0~6 months
Description
Inclusion Criteria:
- Age: 0 to 6 months;
- Subject with cow's milk protein allergy (any clinical signs or symptoms of the skin, gastrointestinal tract, respiratory tract or comfortable tract)
- Unable to breastfeed;
- Vital signs are stable;
- Legal guardian has signed the informed consent.
Exclusion Criteria:
- Subject with congenital and hereditary metabolic diseases;
- Digestive tract obstruction;
- Subject with immunodeficiency diseases;
- Subject who is allergic to known components of amino acid formula powder;
- The investigator judges it is not suitable for the subject to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Negative rate of open food challenge test
Time Frame: From baseline to AAF feeding for 6 months
|
Negative rate =The subjects number with negative results of open food challenge test/total subject number with open food challenge test Unit:% Negative rate range: 0-100% High negative rate indicates the immune tolerance of CMPA infant using AAF
|
From baseline to AAF feeding for 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WAZ(weight for age Z score)
Time Frame: From baseline to AAF feeding for 6 months
|
Z-scores of anthropometric parameters from baseline on weight=Average(The difference between the measured infant weight and the reference infant weight of the same age and sex/the reference infant weight standard deviation) The increase of WAZ indicated that AAF could promote growth and development.
|
From baseline to AAF feeding for 6 months
|
|
HAZ(height for age Z score)
Time Frame: From baseline until AAF feeding for 6 months
|
Z-scores of anthropometric parameters from baseline on height=Average(The difference between the measured infant height and the reference infant height of the same age and sex/the reference infant height standard deviation) The increase of HAZ indicated that AAF could promote growth and development.
|
From baseline until AAF feeding for 6 months
|
|
HCAZ(head circumference for age Z score)
Time Frame: From baseline to AAF feeding for 6 months
|
Z-scores of anthropometric parameters from baseline on head circumference=Average(The difference between the measured infant head circumference and the reference infant head circumference of the same age and sex/the reference infant head circumference standard deviation) The increase of HCAZ indicated that AAF could promote growth and development.
|
From baseline to AAF feeding for 6 months
|
|
SCORAD score
Time Frame: From baseline to AAF feeding for 6 months
|
An SCORAD evaluation scale was evaluated by the investigator at each visit
|
From baseline to AAF feeding for 6 months
|
|
Gastrointestinal symptom score
Time Frame: From baseline to AAF feeding for 6 months
|
An Gastrointestinal symptom evaluation scale was evaluated by the investigator at each visit
|
From baseline to AAF feeding for 6 months
|
|
Respiratory symptom score
Time Frame: From baseline to AAF feeding for 6 months
|
An Respiratory symptom evaluation scale was evaluated by the investigator at each visit
|
From baseline to AAF feeding for 6 months
|
|
Comfort symptom score
Time Frame: From baseline to AAF feeding for 6 months
|
An Comfort symptom evaluation scale was evaluated by the investigator at each visit
|
From baseline to AAF feeding for 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Juan Zhang, colleague
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 20, 2015
Primary Completion (Actual)
February 28, 2019
Study Completion (Actual)
April 1, 2019
Study Registration Dates
First Submitted
November 1, 2018
First Submitted That Met QC Criteria
December 6, 2018
First Posted (Actual)
December 7, 2018
Study Record Updates
Last Update Posted (Actual)
September 6, 2019
Last Update Submitted That Met QC Criteria
September 1, 2019
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20180402 v1.3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cow's Milk Protein Allergy
-
Edetec Indústria Alimentícia S.A.Federal University of Minas Gerais; Faculdade de Ciências Médicas de Minas...CompletedCow's Milk Allergy
-
Laboratorios OrdesaSprim Advanced Life SciencesTerminatedCow's Milk AllergySpain, France
-
Kasr El Aini HospitalEnrolling by invitationCow Milk Protein AllergyEgypt
-
Société des Produits Nestlé (SPN)TerminatedCow Milk Protein AllergySpain
-
Société des Produits Nestlé (SPN)CompletedCow's Milk Protein AllergyPoland, Germany, Italy
-
LactalisCompleted
-
Assiut UniversityUnknown
-
Ain Shams UniversityCompletedCow's Milk Protein AllergyEgypt
-
FrieslandCampinaSprim Advanced Life SciencesCompletedCow's Milk Protein AllergyMexico